Swedish Orphan Biovitrum stock dropped 2.6% to trade at SEK 454.2 as investors reacted to an unresolved U.S. regulatory decision and a contemporaneous analyst price target reduction.
On June 26 the U.S. Food and Drug Administration declined to approve Sobi’s treatment for uncontrolled gout, issuing a Complete Response Letter. The letter asked for additional information tied to chemistry, manufacturing and controls, and singled out data related to contract manufacturing facilities as areas requiring further evidence.
In response, the company said it plans to request a meeting with the FDA to clarify the path to resubmission and that it will coordinate with its contract manufacturing partners to address the deficiencies identified by the regulator.
Adding to near-term selling pressure, Deutsche Bank trimmed its price target on Sobi to SEK 450 from SEK 490 while keeping a Buy rating on the shares. That adjustment, arriving close on the heels of the FDA setback, reinforced investor caution and contributed to the stock’s pullback from its 52-week high of SEK 473.6.
Analyst consensus remains relatively constructive on the stock, with the average 12-month price target at SEK 476.25, but the immediate narrative around the company’s pipeline has been weakened by the regulatory request for more manufacturing data.
The wider market did little to support Sobi on the trading day. Sweden’s OMX Stockholm 30 has been trading in soft territory in recent sessions, providing limited uplift to pharmaceutical names. Global benchmarks were also subdued, with U.S. indexes essentially flat, offering no meaningful positive spillover to European biopharma stocks.
Sobi’s peers in haematology and immunology likewise operated in a muted environment, and there was no sector-wide catalyst to offset the company-specific headwinds facing Sobi.
Taken together, the unresolved manufacturing-related items raised by the FDA, the Deutsche Bank price target cut, and a tepid market backdrop have kept selling pressure on the stock during the session. Even with the decline, Sobi’s shares remain well above their 52-week low of SEK 261.2, reflecting continued market appreciation for its haematology and immunology portfolio.
Summary
Sobi shares fell after the FDA issued a Complete Response Letter requesting additional chemistry, manufacturing and controls information and details on contract manufacturing facilities for its uncontrolled gout therapy. Deutsche Bank lowered its price target to SEK 450 from SEK 490 while maintaining a Buy rating, and a weak broader market offered little support. Analyst consensus still places the average 12-month price target at SEK 476.25.
Key points
- The FDA issued a Complete Response Letter seeking more CMC and contract manufacturing data for Sobi’s uncontrolled gout therapy.
- Deutsche Bank cut its price target to SEK 450 from SEK 490 but kept a Buy rating, amplifying near-term investor caution.
- A muted market environment, including a soft OMX Stockholm 30 and flat U.S. benchmarks, provided limited sector support.
Risks and uncertainties
- Further delays to a U.S. approval could postpone or prevent a potential gout franchise launch, affecting revenue timing for Sobi - this primarily impacts the pharmaceutical and biotech sector.
- Additional manufacturing or contract-facility remediation may be required if the FDA’s requested data are not already sufficient, creating execution risk for manufacturing partners and Sobi.
- A continued weak market backdrop could prolong selling pressure on Sobi and peer stocks in haematology and immunology, limiting near-term upside.